Memory CD4 T Cells Enable Antibody Access to Immunoprivileged Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively deliver antibodies to immunoprivileged tissues such as the brain and peripheral nervous system, which are shielded by barriers that prevent antibody access, posing a challenge for treating infections and diseases in these areas.
Innovation Solution
A method involving the administration of an immunogenic agent to induce an immune response, specifically activating memory CD4 T cells, which then facilitate the access of therapeutic antibodies to immunoprivileged tissues, allowing for targeted treatment of infections and diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tight junctions and barriers are maintained to prevent autoreactive antibody access, then protection against autoimmunity is improved, but antibody access to immunoprivileged tissues for pathogen elimination is blocked
Solution Approach 1:
The patent employs FcRn (neonatal Fc receptor) as an intermediary mechanism that facilitates antibody transport across the blood-brain barrier and blood-nerve barrier. FcRn binds to IgG antibodies in the blood and mediates their transcytosis into the central nervous system and peripheral nervous system, enabling therapeutic antibody delivery without compromising the protective function of tight junctions
Solution Approach 2:
The patent utilizes changes in physiological parameters, specifically pH gradients across the blood-brain barrier, to enable FcRn-mediated antibody transport. FcRn exhibits pH-dependent binding to IgG, with high affinity at acidic pH (endosomal compartment) and low affinity at neutral pH (blood side), allowing directional transport of antibodies into immunoprivileged tissues
2Ease of operation
If conventional antibody administration is used, then simplicity of treatment is maintained, but effective antibody delivery to immunoprivileged sites fails
Solution Approach 1:
The invention leverages the endogenous FcRn receptor system as a natural transport intermediary that can be exploited by therapeutically administered antibodies. By designing antibodies with optimized Fc regions that enhance FcRn binding, the patent achieves improved CNS penetration through an endogenous transport pathway, maintaining simple systemic administration while dramatically improving delivery efficacy to immunoprivileged sites
Data Source
AI summary
The present disclosure relates to compositions and methods for treating or preventing a disease or disorder of immunoprivileged tissue. It is described herein that an immunogenic composition which induces production of memory CD4 T cells allows for the access of a therapeutic antibody to the immunoprivileged tissue.